International Journal of Clinical Case Reports 2024, Vol.14, No.3, 117-131 http://medscipublisher.com/index.php/ijccr 124 6.2 Case study 2: moderna (mRNA-1273) vaccine The Moderna (mRNA-1273) vaccine has also shown high efficacy and safety in clinical trials and real-world settings. In a study involving healthcare personnel, first responders, and other essential workers, the mRNA-1273 vaccine demonstrated a 90% effectiveness in preventing SARS-CoV-2 infection, regardless of symptom status. This study highlighted the vaccine's benefits in real-world conditions, emphasizing its role in protecting working-age adults (Thompson et al., 2021). Another comparative study found that the Moderna vaccine had a higher vaccine effectiveness (93%) against COVID-19 hospitalizations compared to the Pfizer-BioNTech vaccine (88%) among adults without immunocompromising conditions (Self et al., 2021). Further research has shown that a third dose of the Moderna vaccine significantly improves protection against COVID-19-associated hospitalization. Among immunocompetent adults, the vaccine effectiveness was 97% for those who received a booster dose compared to 82% for those who received only two doses. Similarly, among adults with immunocompromising conditions, the effectiveness was 88% for those who received a third dose compared to 69% for two-dose recipients (Tenforde et al., 2022). These findings highlight the importance of booster doses in maintaining high levels of protection, especially among vulnerable populations. 6.3 Case study 3: mRNA rabies vaccine (CV7201) The mRNA rabies vaccine (CV7201) represents a novel approach to rabies immunization, leveraging the same mRNA technology used in COVID-19 vaccines. Although specific data on CV7201 were not provided in the abstracts, the general principles of mRNA vaccine technology suggest that CV7201 would likely exhibit similar safety and immunogenicity profiles. mRNA vaccines work by encoding the antigen of interest, in this case, the rabies virus glycoprotein, which is then translated by the host cells to elicit an immune response. The success of mRNA vaccines like BNT162b2 and mRNA-1273 in preventing COVID-19 provides a strong foundation for the development of other mRNA-based vaccines, including CV7201. The ability to rapidly design and produce mRNA vaccines, coupled with their robust immune responses and favorable safety profiles, makes them a promising platform for addressing various infectious diseases. Future studies will be essential to evaluate the specific efficacy and safety of CV7201 in clinical trials, but the existing data on mRNA vaccine technology are encouraging and suggest a high potential for success. 7 Challenges and Limitations 7.1 Manufacturing and distribution The manufacturing and distribution of mRNA vaccines present significant challenges that need to be addressed to ensure their widespread availability and efficacy. One of the primary challenges is the complexity of the manufacturing process, which involves multiple steps such as in vitro transcription, purification, and formulation. These steps require sophisticated technology and stringent quality control measures to ensure the production of high-quality mRNA vaccines. Additionally, the scalability of the manufacturing process is a critical issue. Large-scale production demands a cost-effective and efficient platform, which is currently a bottleneck in the rapid deployment of mRNA vaccines (Pardi et al., 2020; Rosa et al., 2021; Gote et al., 2023). Another major challenge in the distribution of mRNA vaccines is the requirement for ultra-cold storage conditions. mRNA vaccines, such as those developed for COVID-19, need to be stored at extremely low temperatures to maintain their stability and efficacy. This necessitates a robust cold chain infrastructure, which is not readily available in many parts of the world, particularly in low- and middle-income countries. The logistical complexities of maintaining such a cold chain can hinder the timely and equitable distribution of mRNA vaccines, thereby limiting their global impact (Knezevic et al., 2021; Rosa et al., 2021; Chen et al., 2022). 7.2 Public perception and vaccine hesitancy Public perception and vaccine hesitancy are significant barriers to the successful deployment of mRNA vaccines. Despite the demonstrated efficacy and safety of mRNA vaccines in clinical trials, misinformation and skepticism about their rapid development and novel technology have led to public distrust. Concerns about potential side effects, such as allergic reactions and long-term health impacts, contribute to vaccine hesitancy. Addressing these
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==